Polycystic Kidney Disease | TreatmentTrends | US | 2015
Polycystic kidney disease (PKD) is one of the most common genetic diseases and is characterized by the development and progressive enlargement of fluid-filled cysts in the kidneys. TreatmentTrends® PKD is a syndicated report that provides longitudinal information on market dynamics for the treatment of PKD. This report provides insight into practice patterns, attitudes and perceptions, and projected use of various emerging products. This second report in a series on PKD will primarily focus on autosomal dominant polycystic kidney disease (ADPKD) management in the US.
Related Market Assessment Reports
Report
Systemic Lupus Erythematosus – Access & Reimbursement – Access & Reimbursement – Systemic Lupus Erythematosus (US)
The U.S. systemic lupus erythematosus (SLE) therapy market is largely genericized and off-label. With the exception of GSK’s Benlysta, the firstagents approved for the indication in almost 60…
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Reduced Ejection Fraction (US)
Heart failure with reduced ejection fraction (HFrEF) occurs when the left ventricular ejection fraction (LVEF) is 40% or less. Drug treatment for HFrEF is well established and supported by…
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Preserved Ejection Fraction (US)
Heart failure with preserved ejection fraction (HFpEF) occurs when the left ventricular ejection fraction (LVEF) is 50% or more. Even though physicians’ understanding of the disease’s…
